Research programme: covalent MEK inhibitors - Immuneering
Alternative Names: Covalent-MEK programme - ImmueneeringLatest Information Update: 20 Apr 2022
At a glance
- Originator Immuneering
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours